Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas

Indian Journal of Medical Research

Volumn 131, Issue 4, 2010, Pages 530-535

  Bhansali, A ^a   Walia, R ^a   Dutta, P ^a   Khandelwal, N ^a   Sialy, R ^a   Bhadada, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cabergoline; Dose escalation; Macroprolactinomas

Indexed keywords

CABERGOLINE; CABERLIN; PROLACTIN; STEROID; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTIN BLOOD LEVEL; PROLACTINOMA; QUALITY OF LIFE; SOMNOLENCE; TESTOSTERONE BLOOD LEVEL; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL FIELD DEFECT;

ADULT; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; HUMANS; MALE; MIDDLE AGED; PROLACTINOMA; QUALITY OF LIFE;

EID: 77951068161     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mindermann T, Wilson CB. Age-related and gender related occurrence of pituitary adenomas. Clin Endocrinol 1994; 41: 359-64.
2. Molitch ME, Elton RL, Blackwell RE, Cardwells B, Chang RJ, Jaffe R, et al. Bromocriptine as primary therapy for prolactin - secreting macroadenomas: results of a prospective multicentre study. J Clin Endocrinol Metab 1985; 60: 698-705.
3. Molitch ME. Medical management of prolactin secreting pituitary adenomas. Pituitary 2002; 5: 55-65.
4. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, et al. Giant prolactinomas in men: efficacy of caberoline treatment. Clin Endocrinol 2003; 58: 662-70.
5. Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactin-secreting macroadenoma with once weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 38-43.
6. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24 months treatment on prolactin levels, tumor mass, recovery of pituitary function and semen analysis. J Clin Endocrinol Metab 2004; 89: 1704-11.
7. Abbond CF. Louts ER. Diagnosis of pituitary tumors. Endocrinol Metab Clin N Am 1988: 17: 241-74.
8. Heinemann LA, Moor C, Dinger JC, Stoehr D. Sensitivity and outcome measures of androgens; the AMS scale Health quality life outcomes. Health Qual Life Outcomes 2006; 4: 23.
9. Dash RJ, England BG, Midgley AR Jr., Niswender GD. A specific, non-chromatographic radioiammunoassay for human plasma cortisol. Steroids 1975; 26: 647-61.
10. Inder WJ, Hunt PJ. Glucocorticoid replacement in pituitary surgery: Guidelines for perioperative assessment and management. J Clin Endocrinol Metab 2002; 87: 2745-50.
11. Hagg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of the pituitary - adrenal axis. Clin Endocrinol 1987; 44: 141-6.
12. Ferrari CI, Abstract R, Bevan JS, Brabant G, Ciccarelli E, Mottta T, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 1997; 46: 409-13.
13. Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007; 156: 225-31.
14. De Rose M, Zarrilli S, Vitale G, Di somma C, Orio F, Tauchmanova L, et al. Six months treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89: 621-5.
15. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138: 286-93.
16. Verhert J, Abs R, Maiter D, Vandeweghe M, Velkeniers B, Mockel J, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84: 2518-22.
17. De Rose M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Disarno A, et al. The treatment with cabergoline for 24 months normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol 2006; 64: 307-13.
18. Page SR, Nussey SS. Cabergoline therapy of a large prolactinoma in a bromocriptine - intolerant patient. J Obstet Gynaecol 1989; 10: 156-8.
19. Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs 1996; 51: 954-65.
20. Ferrari C, Barbieri C, Caldava R, Music M, Codecasa F, Paracchi A, et al. Long lasting prolactin lowering effect of cabergoline a new dopamine agonist in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63: 941-5.